Daniel Skiest to Treatment Outcome
This is a "connection" page, showing publications Daniel Skiest has written about Treatment Outcome.
Connection Strength
0.185
-
Skiest DJ, Vazquez JA, Anstead GM, Graybill JR, Reynes J, Ward D, Hare R, Boparai N, Isaacs R. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis. 2007 Feb 15; 44(4):607-14.
Score: 0.033
-
Springer SA, Di Paola A, Azar MM, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial. J Acquir Immune Defic Syndr. 2018 05 01; 78(1):43-53.
Score: 0.018
-
Haessler S, Lagu T, Lindenauer PK, Skiest DJ, Priya A, Pekow PS, Zilberberg MD, Higgins TL, Rothberg MB. Treatment Trends and Outcomes in Healthcare-Associated Pneumonia. J Hosp Med. 2017 11; 12(11):886-891.
Score: 0.017
-
Belforti RK, Lagu T, Haessler S, Lindenauer PK, Pekow PS, Priya A, Zilberberg MD, Skiest D, Higgins TL, Stefan MS, Rothberg MB. Association Between Initial Route of Fluoroquinolone Administration and Outcomes in Patients Hospitalized for Community-acquired Pneumonia. Clin Infect Dis. 2016 07 01; 63(1):1-9.
Score: 0.016
-
Cummins NW, Neuhaus J, Chu H, Neaton J, Wyen C, Rockstroh JK, Skiest DJ, Boyd MA, Khoo S, Rotger M, Telenti A, Weinshilboum R, Badley AD. Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis. EBioMedicine. 2015 Jul; 2(7):706-12.
Score: 0.015
-
Rothberg MB, Zilberberg MD, Pekow PS, Priya A, Haessler S, Belforti R, Skiest D, Lagu T, Higgins TL, Lindenauer PK. Association of guideline-based antimicrobial therapy and outcomes in healthcare-associated pneumonia. J Antimicrob Chemother. 2015 May; 70(5):1573-9.
Score: 0.014
-
Rothberg MB, Haessler S, Lagu T, Lindenauer PK, Pekow PS, Priya A, Skiest D, Zilberberg MD. Outcomes of patients with healthcare-associated pneumonia: worse disease or sicker patients? Infect Control Hosp Epidemiol. 2014 Oct; 35 Suppl 3:S107-15.
Score: 0.014
-
Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK. Comparative effectiveness of macrolides and quinolones for patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). J Hosp Med. 2010 May-Jun; 5(5):261-7.
Score: 0.010
-
Arshad S, Skiest D, Granowitz EV. Subacute onset of paralysis in a person with AIDS. AIDS Read. 2009 Jan; 19(1):32-5.
Score: 0.009
-
Tashima K, Staszewski S, Nelson M, Rachlis A, Skiest D, Stryker R, Bessen L, Overfield S, Ruiz N, Wirtz V. Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection. AIDS. 2008 Jan 11; 22(2):275-9.
Score: 0.009
-
Cenizal MJ, Skiest D, Luber S, Bedimo R, Davis P, Fox P, Delaney K, Hardy RD. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007 Jul; 51(7):2628-30.
Score: 0.008
-
Vazquez JA, Skiest DJ, Tissot-Dupont H, Lennox JL, Boparai N, Isaacs R. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Clin Trials. 2007 Mar-Apr; 8(2):86-97.
Score: 0.008
-
Vazquez JA, Skiest DJ, Nieto L, Northland R, Sanne I, Gogate J, Greaves W, Isaacs R. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis. 2006 Apr 15; 42(8):1179-86.
Score: 0.008
-
Keiser P, Rademacher S, Smith JW, Skiest D, Vadde V. Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients. Am J Med. 1998 Jan; 104(1):48-55.
Score: 0.004